It’s Time for the FDA To Embrace Digital Technology

  • Artvoice | by: Peter J. Pitts |
  • 04/11/2018 12:00 AM
by is licensed under
The FDA’s drug regulators want to know everything. They require pharmaceutical companies to conduct years of testing to prove that experimental medicines are safe and effective.

This rigorous and mostly prudent approach makes perfect sense when evaluating potent biopharmaceutical products. After all, if the FDA makes a mistake it could endanger thousands of patients.

But such excessive caution isn’t warranted when it comes to a new breed of digital technologies designed to make medicines more effective by making patients more compliant. These technologies — which include ingestible, implantable, portable, and app-based monitoring and diagnostic tools — pose minimal safety risks. Therefore, FDA regulators should subject these products to less scrutiny. That would speed the approval process and enable patients to access these tools sooner.

Patients and their families are excited, rather than fearful or suspicious, about the potential of digital technologies.
Consider Abilify MyCite, a pill with a sensor that digitally tracks whether schizophrenia patients have ingested their medication. This technology could help boost abysmally low rates of medication adherence. Currently, three out of five schizophrenia patients do not take prescriptions as prescribed.

Enabling caregivers and family members to check whether patients have taken their pills could prevent patients’ mental health from deteriorating. The technology could spare patients and families much anguish and prevent costly hospitalizations, thereby lowering overall healthcare spending. Fortunately, the FDA approved the technology in November.

Researchers are incorporating similar sensors into other medications too. The tools could remind dementia patients to take their medicines. Or they could help a parent know if her child actually swallowed her pill or stuck it in her cheek and spit it out later.
 
Article Photo Credit: by is licensed under
Sign Up for Our Email Newsletter

RECENT NEWS

Truth vs. Tort
  • CMPI
  • 07/18/2024 12:00 AM

Truth vs. Tort

New litigation alleging preterm infant formula and human milk fortifiers cause NEC distorts the facts and ignores what th...  Read more

New CMPI Book: And Nothing But the Truth

New CMPI Book: And Nothing But the Truth

Healthcare evolution, in technology and policy, is a never-ending parade of complicated and contradictory truths. This bo...  Read more

Tort bar’s newest collateral damage: Preterm babies

Tort bar’s newest collateral damage: Preterm babies

Lawsuits allege links between intestinal disease, infant formula and human milk fortifiers...  Read more

DRUGWONKS BLOG